Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 221,456,730 papers from all fields of science
Search
Sign In
Create Free Account
response to lapatinib
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Jinlei Ding
,
Yating Yao
,
+11 authors
Hailing Cheng
Cancer Letters
2020
Corpus ID: 211004897
2018
2018
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
C. Savastano
,
F. Lombardi
ABOUTOPEN
2018
Corpus ID: 81679866
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies…
Expand
2013
2013
Determination of the Proteomic Response to Lapatinib Treatment using a comprehensive and reproducible ion-current-based proteomics strategy.
K. O'Connell
,
Jun Li
,
+5 authors
R. O'Connor
Journal of Proteomics and Genomics research
2013
Corpus ID: 20820689
Lapatinib, a small molecule tyrosine kinase inhibitor is currently used in the treatment of HER2-positive breast cancer. The aim…
Expand
2011
2011
Durable Response to Lapatinib Plus Capecitabine in Trastuzumab-Resistant HER2 Over-expressing Metastatic Breast Cancer
Peng-Yu Chen
,
Mei-Ching Liu
,
C. Chen
,
M. Tsou
,
Lingxiao Huang
,
Chuyuan Chen
2011
Corpus ID: 74149548
HER2-directed therapy has become an important agent in the treatment of metastatic breast cancer, and has altered the natural…
Expand
2010
2010
Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
C. Moelans
,
R. D. de Weger
,
P. V. van Diest
Clinical Cancer Research
2010
Corpus ID: 8582256
We have read with great interest the article by Downey et al. on chromosome 17 polysomy without HER2 amplification and prediction…
Expand
2009
2009
EGFR Gene Copy Number and Response to Lapatinib/Capecitabine in HER2 Positive Metastatic Breast Cancer Patients Pretreated with Trastuzumab.
A. Fabi
,
V. Graziano
,
+7 authors
F. Cognetti
2009
Corpus ID: 72006870
Background: Lapatinib (L) is a potent and selective dual inhibitor of EGFR and HER2. In HER2 positive metastatic breast cancer…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE